As­traZeneca stops lung can­cer tri­al ear­ly, af­ter star drug Tagris­so in­duces 'over­whelm­ing' ef­fi­ca­cy

A piv­otal lung can­cer tri­al test­ing Tagris­so, As­traZeneca’s best­selling on­col­o­gy ther­a­py, has been halt­ed due to “over­whelm­ing” ef­fi­ca­cy.

The 682 pa­tient-tri­al, ADAU­RA, was eval­u­at­ing the drug against a place­bo in non-small cell lung can­cer pa­tients with EGFR mu­ta­tions who had un­der­gone tu­mor re­sec­tion and op­tion­al, stan­dard post­op­er­a­tive ad­ju­vant chemother­a­py. In the Tagris­so arm, pa­tients were to be treat­ed with the 80 mg drug once-dai­ly for three years, or un­til the can­cer re­turned — and the da­ta read­out was sched­uled for 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.